Alkermes to acquire Avadel for up to $2.1 billion
Oct 22 (Reuters) - Alkermes ALKS.O said on Wednesday it will acquire Avadel Pharmaceuticals AVDL.O for up to $2.1 billion gaining access to the company's approved excessive daytime sleepiness drug. (Reporting by Sriparna Roy in Bengaluru; Editing by Tasim Zahid) ((Sriparna.Roy@thomsonreuters.com;))
Recent news on Avadel Pharmaceuticals
See all newsBrief: Alkermes PLC Completes Acquisition Of Avadel Pharmaceuticals PLC, Accelerating Entry Into Sleep Medicine Market
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 08:10 AM
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet